A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Recruiting now · Phase 2

Conditions studied: Atopic Dermatitis (AD)

In brief

This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.

Key facts

Study ID

NCT07230483

Run by

Keymed Biosciences Co.Ltd

People needed

246

Starts

2025-12-01

Expected to finish

2027-12-01

Last updated by the study team

2025-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
• Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.

You may not qualify if…

• Not enough washing-out period for previous therapy.
• Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.